University of Patras
Ο ρόλος της φλεγμονής και του οξειδωτικού stress στον ινσουλινοεξαρτώμενο σακχαρώδη διαβήτη
Abstract
dc:descriptionINTRODUCTION: Diabetes mellitus type 1 (DM1) is a chronic disease of childhood and young adulthood and is often accompanied by severe micro- and macro-vascular complications. Key role in their development plays excess glucose through non-enzymatic interaction with molecules and final production of advanced glycation end products, AGEs (main representative the Ne-(carboxymethyl)lysine, CML). The AGEs linked to their receptor RAGE (mainly) induce the intracellular production of oxidants (malondialdehyde, MDA), proinflammatory (cyclooxygenase-2, COX-2) and pre-thrombotic agents. This leads to the activation of blood mononuclear cells (PBMCs), recruitment to the sub-endothelial space through adhesion molecules (intercellular adhesion molecule-1, ICAM-1; vascular cell adhesion molecule-1, VCAM-1) and development of vascular malfunction. Protective role in these processes play the soluble forms of RAGE, sRAGE, who are produced by alternative splicing of the RAGE gene or by enzymatic catalysis (matrix metalloproteinase-9, MMP-9) and remove AGEs from the circulation, inhibiting their actions. Also protective antioxidant mechanisms are developed and evaluated by methods such as plasma ferric reducing ability (FRAP). AIM / MATERIALS - METHODS: In order to investigate the possible role of inflammatory processes and oxidative stress in the development of diabetic complications, in PBMCs of 110 children and young adults (age: 4-29 years) with DM1 and 124 non-diabetic age-matched controls, we studied: 1) by PCR, gene expression (mRNA) of: COX-2, RAGE, MMP-9, ICAM-1, VCAM-1 and 2) by Western blotting, protein expression of: COX-2, RAGE. In the plasma of the same individuals we measured: 3) by ELISA, plasma levels of: sRAGE, CML, MMP-9 and 4) by spectrophotometry, the MDA plasma levels and FRAP. RESULTS: The study showed that: RAGE gene expression was increased in: 1) DM1 patients compared with controls, 2) DM1 patients >13yrs old compared with their respective controls and 3) DM1 patients with >5yr disease duration compared with controls. esRAGE protein expression presented: 1) increasing trend in DM1 patients compared to controls, a trend that remained even after separation by age (≤ or >13yrs old), 2) increased in DM1 patients with disease duration >5yrs compared to DM1 patients with disease duration ≤5yrs and controls. COX-2 gene expression was increased: 1) in DM1 patients in total, 2) in DM1 patients with age >13yrs and 3) those with >5yrs of disease duration, compared to their respective controls. COX-2 protein expression showed: 1) reduction trend in total DM1 patients compared with their respective controls, trend that remained regardless of the duration of the patients' disease, 2) reduction in DM1 patients >13yrs old compared to DM1 ≤13yrs old patients and their age matched controls, 3) reduction in DM1 patients with HbA1c≤7% compared to DM1 patients with HbA1c:7,1-8% and their respective controls. MMP-9 gene expression showed no significant difference between DM1 patients and controls, in total or in separated groups. MMP-9 plasma levels: 1) showed no significant differences between the DM1 patients and their respective controls in total or when grouped according to their age or DM1 duration, 2) were significantly increased in DM1 patients while increasing levels of HbA1c, with maximum in HbA1c:9% and followed a gradual reducing with HbA1c>9%. ICAM-1 gene expression showed no significant difference between DM1 patients and their controls in total or in separated groups. VCAM-1 gene expression was: 1) reduced in DM1 patients compared with controls, in total, independently of the duration of the disease, 2) decreased in patients DM1>13yrs old compared with their respective controls. sRAGE plasma levels: 1) showed no significant differences between DM1 patients and the controls in total or when grouped according to their age or DM1 duration, 2) showed an increasing trend in DM1 patients with increased levels of HbA1c (especially with HbA1c>9%). CML plasma levels showed: 1) increasing trend in DM1 patients compared with the controls in total, 2) increase in DM1 patients ≤13yrs old and those with disease duration ≤5yrs, compared with their respective controls. MDA plasma levels were increased in DM1 patients compared to controls, independently of the age or the duration of the disease. FRAP plasma levels showed: 1) increase in DM1 patients compared to controls, in total, 2) increasing trend in DM1 patients aged ≤ and >13yrs and 3) in DM1 patients with disease duration ≤5yrs and >5yrs, compared to controls. CONCLUSIONS: It seams that younger DM1 patients develop protective mechanisms against glycation, inflammation and oxidative stress that protect them from the development of diabetic complications.
Degree
thesis:*- Grantor dc:publisher
- University of Patras
- Year dc:date
- 2016
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Koutroumani, Nikolitsa
- Κουτρουμάνη, Νικολίτσα
Subjects
dc:subject × 12Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/40205